Encompass Health (NYSE:EHC) Price Target Raised to $160.00 at Bank of America

Key Points

• Bank of America has raised its price target for Encompass Health (NYSE:EHC) from $145.00 to $160.00, indicating a potential upside of 28.61% from its previous close, and maintains a "buy" rating on the stock.
• Other analysts have also increased their price targets, with KeyCorp setting it at $135.00 and Truist Financial raising it to $140.00, contributing to an average consensus price target of $137.71.
• In its latest earnings report, Encompass Health surpassed expectations with an EPS of $1.40, and its quarterly revenue rose by 12.0% year over year, totaling $1.46 billion.

Encompass Health (NYSE:EHC - Free Report) had its price objective lifted by Bank of America from $145.00 to $160.00 in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

EHC has been the topic of a number of other research reports. Stephens raised shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price objective on the stock in a research report on Thursday, June 5th. KeyCorp increased their price objective on shares of Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 27th. UBS Group increased their price objective on shares of Encompass Health from $130.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Wall Street Zen cut shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Truist Financial increased their price objective on shares of Encompass Health from $135.00 to $140.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat, Encompass Health currently has an average rating of "Buy" and an average price target of $137.71.

Encompass Health Trading Down 0.6%

EHC traded down $0.76 during trading on Wednesday, reaching $126.04. 551,583 shares of the stock traded hands, compared to its average volume of 633,963. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $12.69 billion, a PE ratio of 24.67, a P/E/G ratio of 2.22 and a beta of 0.92. The stock's 50-day moving average is $117.50 and its 200 day moving average is $112.76. Encompass Health has a 12 month low of $87.85 and a 12 month high of $127.15.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.20 by $0.20. The company had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The business's revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.11 EPS. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. Equities analysts anticipate that Encompass Health will post 4.8 earnings per share for the current year.

Encompass Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be paid a $0.19 dividend. This is a positive change from Encompass Health's previous quarterly dividend of $0.17. The ex-dividend date is Wednesday, October 1st. This represents a $0.76 annualized dividend and a yield of 0.6%. Encompass Health's dividend payout ratio (DPR) is 13.31%.

Insider Buying and Selling

In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $123.59, for a total value of $126,061.80. Following the completion of the sale, the executive vice president owned 18,846 shares in the company, valued at approximately $2,329,177.14. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.00% of the company's stock.

Institutional Investors Weigh In On Encompass Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in EHC. Baird Financial Group Inc. increased its stake in Encompass Health by 1,147.0% in the 4th quarter. Baird Financial Group Inc. now owns 2,494 shares of the company's stock valued at $230,000 after buying an additional 2,294 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Encompass Health by 71.3% during the 4th quarter. Captrust Financial Advisors now owns 7,065 shares of the company's stock worth $652,000 after purchasing an additional 2,941 shares during the last quarter. Cetera Investment Advisers increased its stake in shares of Encompass Health by 7.7% during the 4th quarter. Cetera Investment Advisers now owns 14,515 shares of the company's stock worth $1,340,000 after purchasing an additional 1,036 shares during the last quarter. D. E. Shaw & Co. Inc. increased its stake in shares of Encompass Health by 335.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 62,994 shares of the company's stock worth $5,817,000 after purchasing an additional 48,517 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Encompass Health by 9.9% during the 4th quarter. Deutsche Bank AG now owns 9,814 shares of the company's stock worth $906,000 after purchasing an additional 883 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.